Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- COPD exacerbations
Fast therapy initiation is not much better than expected
- Galenic systems
Advantages of topical pharmacotherapy – Update 2025
- Collagenoses
Scleroderma – Current recommendations for diagnosis and therapy 2025
- Psychedelics and related drug classes
Ritual, party or new therapy? Psychedelics and more: clinically illuminated
- Acute sinusitis: real-world study on first-line therapy
Focusing on a rational therapeutic approach beyond antibiotics
- DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline
Stroke prevention for atrial fibrillation 2025
- Prurigo nodularis and AD
Effective itch relief through inhibition of the IL-31 signaling pathway
- From symptom to diagnosis